The government has given approval to drug firms includingAurobindo Pharma and Karnataka Antibiotics & Pharmaceuticals under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country. The setting up of plants under the scheme will lead to total committed investment of Rs 3,761 crore by the companies and employment generation for around 3,825 people,the Ministry of Chemicals and Fertilizers said in a statement. The applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production ofPenicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA isRs 813 crore, it added.
First set of five bulk drug, pharma input projects under PLI scheme cleared
January 22, 2021
×
The government has approved the first set of five pharma projects, worth a total committed investment of ₹3,761 crore, under the Production Linked Incentive (PLI) scheme for promoting domestic manufacture of bulk drugs and active pharmaceutical ingredients (APIs).
An official statement said on Friday the projects relate to four fermentation-based key starting materials and APIs such as penicillin G, 7-ACA (7-aminocephalosporanic acid), erythromycin thiocyanate and clavulanic acid, which are all entirely imported now.
An expert committee set up by the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilisers identified 53 APIs for which the country is mainly import dependent. These bulk drugs accounted for 63 per cent of the total pharmaceutical imports. Subsequently, an Empowered Committee headed by Amitabh Kant, CEO NITI Aayog, was set up last year to design the PL
Aurobindo, Kinvan, K taka Antibiotics first to get PLI for drugs
While Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid
Joe C Mathew | January 22, 2021 | Updated 22:23 IST
Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products
The central government has announced the list of the first three companies - Hyderabad based Aurobindo Pharma, Kinvan Pvt Ltd, Mumbai and public sector firm Karnataka Antibiotics and Pharmaceuticals - that have qualified for financial support under the production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs), drug intermediates and active pharmaceutical ingredients (APIs).